Saturday 17 October 2026
Export ENVB’s income statement to Excel — free account
Enveric Biosciences, Inc.
ENVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 93.5% and free cash flow fell 29.3%, each against the same quarter a year earlier.
1.38
0.01
−0.72%
Follow ENVB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (235.48%) | (257.95%) | (420.48%) | (303.64%) |
+8 more TTM periods Free account |
|
| (193.53%) | (218.01%) | (296.67%) | (245.75%) | ||
ROIC |
0.00% | (3,379.93%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(150.85%) | (230.02%) | (290.40%) | (325.39%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.15) | (5.30) | (24.32) | (24.48) | |
Free Cash Flow |
(8.56) | (8.01) | (8.14) | (7.67) | |
| Other line items | |||||
Cash ROIC |
(52.27%) | (80.31%) | (91.94%) | (106.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(29,094.67) | — | — | — | |
Operating CF/Net income |
0.71 | 0.69 | 0.67 | 0.68 | |
Depreciation/Fixed assets |
1.88 | 1.31 | 1.26 | 1.24 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.15) | (5.30) | (24.32) | (24.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates